In the continuing search for effective treatments for cancer, an emerging paradigm is the use of nanotechnology to uncap the full potential of existing chemotherapy agents . Integral physicochemical properties of nanovectors can be modulated to improve the antitumor efficacy of chemotherapeutic agents . For example, the shape and size of nanostructures can play a deterministic role in the biological outcome . Similarly, surface modifications to increase hydrophilicity can mask from the reticuloendothelial system, thereby increasing circulation time and altering the pharmacokinetics of the active agents . Such formulation accumulate preferentially in the tumors due to the unique leaky tumor vasculature coupled with impaired intratumoral lymphatic drainage, which contributes to an enhanced permeation and retention (EPR) effect . Indeed, these formulations were shown to deliver between 5–11× more to Kaposi sarcoma lesions than to normal skin . Similarly, the tumor paclitaxel concentration-time area under the curve was found to be 33% higher when administered as a nano-paclitaxel nanoparticle, and is currently approved for use in metastatic breast cancer .
We even took to next level to have nanomedicine engineered with two active molecules, hence making it much more effective than nano-paclitaxel alone. HYBRID-NANOENGINEERING™ IS A NEXT GENERATION OF NANOMEDICINE.
Cancer therapy using cytotoxic drugs has negative side effects on normal cells. To date, the pharmaceutical industry has not been able to produce a drug that can provide the dual functions of protecting normal cells while sensitizing tumor cells to cancer therapy using two or more drugs in one formulation and that too nanomedicine. With the discovery of HYBRID-NANOENGINEERING™, we have discovered a new and better treatment for cancer therapy problem.
Our team is strong and experienced, and all have more than 15 yr industry experience. Our Scientific Advisory Board is composed of experts with a variety of expertise related to drug discovery and drug development.